NCT04092725 is a Phase 1 clinical trial of DAB in Pharmacokinetics, sponsored by Scynexis, Inc..

Who is sponsoring NCT04092725?

NCT04092725 is sponsored by Scynexis, Inc..

What drugs are being tested in NCT04092725?

Interventions in NCT04092725: DAB, SCY-078 plus DAB.

What condition does NCT04092725 study?

NCT04092725 studies Pharmacokinetics.

Is NCT04092725 still recruiting?

NCT04092725 is currently completed. Last updated 2 September 2020.

Last reviewed 2020-09-02 · How we verify

NCT04092725

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects

Completed Phase 1 Last updated 2 September 2020

What this trial tests

Phase 1 trial testing DAB in Pharmacokinetics in 36 participants. Completed in 3 January 2020.

Timeline

9 September 2019

Primary endpoint
3 January 2020

3 January 2020

Quick facts

Lead sponsor	Scynexis, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	36
Start date	9 September 2019
Primary completion	3 January 2020
Estimated completion	3 January 2020
Sites	1 location across Australia

Drugs / interventions tested

DAB — full drug profile →
SCY-078 plus DAB — full drug profile →

Conditions studied

Pharmacokinetics — all drugs for Pharmacokinetics →

Sponsor

Scynexis, Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 open-label, randomized, two-period, crossover study to evaluate the effect of repeated oral doses of SCY-078 (Ibrexafungerp) on the pharmacokinetics of dabigatran administered orally to healthy subjects.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.
Hoenigl M, Arastehfar A, Arendrup MC, Brüggemann R, et al · · 2024 · cited 86× · PMID 38602408 · DOI 10.1128/cmr.00074-23
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.
Jallow S, Govender NP. · · 2021 · cited 86× · PMID 33668824 · DOI 10.3390/jof7030163
Antifungal resistance, combinations and pipeline: oh my!
Stover KR, Hawkins BK, Keck JM, Barber KE, et al · · 2023 · cited 10× · PMID 38021410 · DOI 10.7573/dic.2023-7-1
Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science.
Walley AH, Dupuis LN, Woodahl EL, Killam SR. · · 2025 · cited 2× · PMID 40970688 · DOI 10.1111/cts.70362

Verify or expand the search:

Other recruiting trials for Pharmacokinetics

Currently open trials in the same condition.

NCT07583407 — Pharmacokinetics of Kava and Kratom Alone and in Combination · NA · recruiting
NCT07422285 — Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Do · Phase 1 · recruiting
NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
NCT06859723 — High Potency Cannabis: Acute and Protracted Effects · Phase 1 · recruiting
NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting

Other Scynexis, Inc. trials

Trials by the same sponsor.

NCT06954493 — Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp · Phase 1 · completed
NCT05668429 — ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects · Phase 1 · completed
NCT05178862 — A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed b · Phase 3 · terminated
NCT05908682 — Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes · recruiting
NCT05399641 — Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04092725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Scynexis, Inc.
Last refreshed: 2 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04092725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing